 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Alnylam Shares Still Flying on ATTR Results, But Not All RNAi Drug Firms Get as Big a Boost on Data
August 02, 2012
Alnylam Shares Still Flying on ATTR Results, But Not All RNAi Drug Firms Get as Big a Boost on Data
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Key RNAi-Based Drugs in the Clinic
April 29, 2010 / Gene Silencing News - Silence Starts Phase Ib/IIa Trial of Cancer Drug as It Looks to Balance Pipeline
May 30, 2013 / Gene Silencing News - Silence Plans $28.6M Stock Sale to Fund Expansion of Staff, Pipeline
April 11, 2013 / Gene Silencing News - Tekmira to Present Cancer Drug Data at AACR, Aims for Phase II by Year-End
March 28, 2013 / Gene Silencing News - After Losing Another CEO, Silence Management Aims to Fill in Corporate Gaps
March 21, 2013 / Gene Silencing News